Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 25 Issue 12, December 2007

The emergence of new viral pathogens, the increasing prevalence of chronic viral diseases and the rise of drug resistant viral strain has increased demand for new antiviral strategies. This focus provides an update on the science and business of antiviral R&D in the biotech sector. Cover art by Susanne Harris.

Volume 25 Issue 12

Subscribe

Editorial

  • Animal vaccines prevent disease but founder because of political motivations.

    Editorial

    Advertisement

  • In Europe, no one apparently wants to listen if you have good news about genetically modified organisms (GMOs).

    Editorial
Top of page ⤴

News

Top of page ⤴

News in Brief

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • With the market for companion animals and veterinary products booming, will the animal biotech sector finally receive the financial resources it has so long needed? Jim Kling reports.

    • Jim Kling
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

Top of page ⤴

News & Views

Top of page ⤴

Editorial

  • Interferon (IFN)-α has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.

    Editorial
Top of page ⤴

Profile

  • Almost 15 years after Ian Frazer began the work that created the first vaccine to prevent cervical cancer caused by human papilloma virus (HPV), the 54-year-old immunologist is using his newfound prominence to educate others about treating HPV and to pass along the lessons he's learned about drug development.

    • Mark Ratner
    Profile
Top of page ⤴

News Feature

  • A rash of failures for hepatitis C drugs, conflicting theories about the immune system's role and the looming issue of drug resistance make it impossible to predict when or how new therapies will make an impact. Ken Garber reports.

    • Ken Garber
    News Feature
Top of page ⤴

Commentary

  • Will our increasing understanding of virus-host interactions translate into a new generation of antiviral therapeutics or steer us toward an expensive journey to nowhere?

    • Seng-Lai Tan
    • Gopinath Ganji
    • Michael G Katze
    Commentary
Top of page ⤴

Feature

  • Small molecules have dominated antivirals for decades, but other approaches are needed and biologics could show the way.

    • Jeffrey L Fox
    Feature
Top of page ⤴

Patents

Top of page ⤴

Commentary

  • As sequencing technology and prediction algorithms improve, HIV genotyping and coreceptor usage prediction are likely to play an increasingly important role in guiding patient prognosis and treatment selection.

    • Thomas Lengauer
    • Oliver Sander
    • Rolf Kaiser
    Commentary
Top of page ⤴

Perspective

Top of page ⤴

Review Article

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

Careers and Recruitment

  • Consultants can apply scientific thinking to solve complex business problems, often with immediate effects and tangible impact.

    • Samarth Kulkarni
    Careers and Recruitment
Top of page ⤴

People

Top of page ⤴

Focus

  • This issue provides several articles focusing on antiviral therapy. Additional material, brought together in a joint focus with Nature Reviews Drug Discoverysupported by our principal sponsor Pfizer and our supporting sponsor Gilead.

    Focus
Top of page ⤴

Search

Advanced search

Quick links